WO2007051314A1 - Composés curcuminoïdes dans l'inhibition de l'inhibiteur-1 de l'activateur du plasminogène - Google Patents

Composés curcuminoïdes dans l'inhibition de l'inhibiteur-1 de l'activateur du plasminogène Download PDF

Info

Publication number
WO2007051314A1
WO2007051314A1 PCT/CA2006/001817 CA2006001817W WO2007051314A1 WO 2007051314 A1 WO2007051314 A1 WO 2007051314A1 CA 2006001817 W CA2006001817 W CA 2006001817W WO 2007051314 A1 WO2007051314 A1 WO 2007051314A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compound
cancer
halogen
pai
Prior art date
Application number
PCT/CA2006/001817
Other languages
English (en)
Inventor
Latchezar S. Trifonov
Jean Vaugeois
Bhavna Gaikwad
Robert S. Greenfield
Original Assignee
American Diagnostica Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Diagnostica Inc. filed Critical American Diagnostica Inc.
Publication of WO2007051314A1 publication Critical patent/WO2007051314A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C07C49/248—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Definitions

  • the invention relates generally to pharmaceutical compounds.
  • the invention relates to pharmaceutical compounds derived from curcumin, which act as inhibitors of plasminogen activator inhibitor-1 (PAI-I).
  • PAI-I plasminogen activator inhibitor-1
  • PAI-I is a serine protease inhibitor which acts on its targets, urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), thereby regulating the conversion of plasminogen to plasmin in the fibrinolytic cascade.
  • uPA urokinase plasminogen activator
  • tPA tissue plasminogen activator
  • PAI-I has also been shown to be elevated in disease conditions such as polycystic ovary syndrome 8 , bone loss due to estrogen deficiency 9 , and thus inhibition of PAI-I may have therapeutic and prophylactic benefits for these conditions. It appears that PAI-I is normally present at low levels in circulating plasma.
  • Inhibition of plasma PAI-I thus has promise as a treatment or prophylactic measure in mammals, in particular humans, for various thrombotic- related disease conditions including deep vein thrombosis, coronary artery disease, pulmonary fibrosis and polycystic ovary syndrome.
  • curcumin (diferuloylmethane) is a polyphenol derived from the plant species Curcuma longa, commonly known as the spice, turmeric. Turmeric has been found to reduce plasma levels of PAI-I. 10 ' 11 Traditionally, turmeric has been used for wound healing and other medicinal purposes. [0005] Aspects of the biochemistries of uPA, tPA, and PAI-I are reasonably well known. uPA acts by cleaving a single peptide bond in plasminogen, converting it into plasmin, which proceeds to degrade a broad spectrum of proteins including fibrin, fibronectin, and laminin. Plasmin also has other effects including affecting various growth factor systems.
  • uPA has been identified in extracts from human lung, colon, breast, and other tissues, including tumor tissues of various types.
  • One of the natural controls for uPA activity is PAI-I, which inactivates into a latent form. This inactivation may be prevented by binding to vitronectin. PAI-I seems to inhibit receptor-bound uPA, as well as uPA in solution.
  • Studies conducted on patients have shown that a high PAI- 1 level is associated with a poor prognosis in cancer patients, including high risk breast cancer patients and those with lung adenocarcinoma, suggesting that PAI-I promotes tumor growth, invasion, or metastasis.
  • the present invention therefore relates to curcuminoid compounds which inhibit PAI-I.
  • the compounds of the invention inhibit the inhibitory activity of PAI-I towards uPA, thereby up-regulating uPA. It is believed that these compounds also inhibit the interaction of PAI-I with tPA and with vitronectin.
  • the invention thus provides according to a first aspect, for a compound of formula IA or IB:
  • Q x and Q 2 can each be independently selected from optionally substituted phenyl, optionally substituted thio- phene and optionally substituted fused aryl group which optionally contains a hetero atom.
  • Qi may be selected from optionally substituted phenyl, optionally substituted thiophene and optionally substituted fused aryl group which optionally contains a hetero atom
  • Q 2 is selected from Ci to C 6 linear, branched, saturated, unsaturated or cyclic alkyl group.
  • the invention provides for a compound of formula II:
  • R 5 to R i4 are each independently selected from H, OH, SH, NO 2 , SO 2 , halogen and Ci to C 6 linear, branched, saturated, unsaturated, cyclic, bicyclic, fused, substituted, or unsubstituted alkyl or aryl group optionally containing at least one halogen and/or hetero atom; or at least two consecutive groups R 5 to Ri 4 form a substituted or un-substituted aromatic or aliphatic cycle which optionally contains at least one halogen and/or hetero atom; Xi and X 2 are each independently selected from OH, O and S; and denotes a chemical bond that is present or absent, and a pharmaceutically acceptable salt thereof.
  • the invention provides for a compound of formula III:
  • R 5 to R 9 are each independently selected from H, OH, SH, NO 2 , SO 2 , halogen and Ci to C 6 linear, branched, saturated, unsaturated, cyclic, bicyclic, fused, substituted, or unsubstituted alkyl or aryl group optionally containing at least one halogen and/or hetero atom; or at least two consecutive groups R 5 to Ri 4 form a substituted or un-substituted aromatic or aliphatic cycle which optionally contains at least one halogen and/or hetero atom; Xi and X 2 are each independently selected from OH, O and S; and denotes a chemical bond that is present or absent, and a pharmaceutically acceptable salt thereof.
  • R i5 and Ri 6 are each independently a Ci to C 6 linear, branched, saturated, unsaturated, cyclic, fused, substituted or unsubstituted aromatic or alkyl group optionally containing at least one halogen and/or hetero atom, and a pharmaceutically acceptable salt thereof.
  • the invention provides for a compound of formula VI:
  • R i7 and Ri 8 are each independently selected from halogen, OH, SH and Ci to C 6 linear, branched, saturated, unsaturated, cyclic, bicyclic, fused substituted or unsubstituted alkyl or aryl group optionally containing at least one halogen and/or hetero atom, and a pharmaceutically acceptable salt thereof.
  • the invention provides for a compound of formula VII:
  • R 5 to R 9 are each independently selected from H, OH, SH, NO 2 , SO 2 , halogen and Ci to C 6 linear, branched, saturated, unsaturated, cyclic, bicyclic, fused, substituted, or unsubstituted alkyl or aryl group optionally containing at least one halogen and/or hetero atom; or at least two consecutive groups R 5 to R 9 form a substituted or un-substituted aromatic or aliphatic cycle which optionally contains at least one halogen and/or hetero atom.
  • R 6 and Ru can be each independently selected from H and ORi 9 , wherein Ri 9 is a Ci to C 6 alkyl, alkenyl or aryl group; R 7 and R 12 can be each independently selected from OH and OR 2O , R 20 being a Ci to C 6 alkyl, alkenyl or aryl group or CR21COOR2 1 , R21 being H, an alkyl or an alkenyl group, or each independently R 6 and R 7 or Ru and Ri 2 form a cycle containing a heteroatom; and R 8 and Ri 3 can be each independently selected from H; halogen; NO 2 ; COOH; ArS; ArSO 2 ; CH 2 OR 22 , R 22 being H or an alkyl, alkenyl or arylalkyl group; CH 2 R 23 , R 23 being 1-pyrrolidinyl or 1-morpholinyl; and CH 2 N(CH 2 CH 2 ) 2 NR 24 , R 24
  • the hetero atom can be O, S or N, and the halogen atom can be Cl, Br or I.
  • the invention relates to any one of the compounds listed below.
  • the invention also relates to pharmaceutically acceptable salts of the above compounds, as well as pharmaceutical compositions and preparations which comprise one or more of these compounds.
  • the invention relates to enol forms of the compounds according to the invention.
  • Salt forms of the compounds include but are not limited to sodium, potassium, calcium, magnesium salts as well as hydrochlorides, hydrobromides and sulfates. Salt forms of the compounds may also be salts of organic acids including acetic, fumaric, maleic, citric, tartaric salts, or the like. Other useful salt forms of these compounds may comprise pharmaceutically acceptable inorganic and organic bases including hydroxides, carbonates or bicarbonates of the therapeutically acceptable alkali metals or alkaline earth metals, such as sodium potassium, magnesium, calcium and the like.
  • Acceptable organic bases include amines, such as benzylamine, mono-, di- and trialkylamines, preferably those having alkyl groups of form 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, such as methylamine, dimethylamine, trimethylamine, ethyl- amine, diethylamine, triethylamine, mono-, di-, and triethanolamine.
  • amines such as benzylamine, mono-, di- and trialkylamines, preferably those having alkyl groups of form 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, such as methylamine, dimethylamine, trimethylamine, ethyl- amine, diethylamine, triethylamine, mono-, di-, and triethanolamine.
  • alkylene diamines containing up to 6 carbon atoms such as hexameth- ylenediamine; cyclic saturated or unsaturated bases containing up to 6 carbon atoms, including pyrrolidine, piperidine, morpholine, piperazine and their N- alkyl and N-hydroxyalkyl derivatives, such as N-methyl-morpholine and N-(2- hydroxyethyl)-piperidine, or pyridine.
  • Quaternary salts may also be formed, such as tetralkyl forms, such as tetramethyl forms, alkyl-alkanol forms, such as methyl-triethanol or trimethyl-monoethanol forms, and cyclic ammonium salt forms, such as N-methylpyridinium, N-methyl-N-(2-hydroxyethyl)-morpho- linium, N,N-dimethylnnorpholinium, N-methyl-N-(2-hydroxyethyl)-morpho- linium, or N,N-dimethyl-piperidinium salt forms.
  • tetralkyl forms such as tetramethyl forms
  • alkyl-alkanol forms such as methyl-triethanol or trimethyl-monoethanol forms
  • cyclic ammonium salt forms such as N-methylpyridinium, N-methyl-N-(2-hydroxyethyl)-morpho- linium, N,N-dimethylnnorpholinium, N-methyl-N
  • the compounds of the present invention are useful in the treatment, inhibition, prevention or prophylaxis in a mammal, preferably in a human, of processes which involve the production and/or action of PAI-I.
  • the compounds are useful in the treatment or prevention of at least some of the following: noninsulin dependent diabetes mellitus and cardiovascular disease caused by such conditions; prevention of thrombotic events associated with coronary artery and cerebrovascular disease; inhibiting the disease process involving the thrombotic and prothrombotic states which include atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, blood clotting disorders, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery (eg.
  • diseases associated with extracellular matrix accumulation including, but not limited to, renal fibrosis, chronic obstructive pulmonary disease, polycystic ovary syndrome, restenosis, renovascular disease and organ transplant rejection; malignancies and diseases associated with neoangiogenesis (such as diabetic retinopathy); cancer, including, but not limited to, breast, ovary, colon, central nervous system, kidney and prostate cancers, and as imaging agents for the identification of metastatic cancers; myelofibrosis with myeloid metaplasia by regulating stromal cell hyperplasia and increases in extracellular matrix proteins; diabetic nephropathy and renal dialysis associated with nephropathy; septicemia, obesity, insulin resistance, proliferative diseases such as psoriasis, improving coagulation homeostasis, cerebrovascular disease, microvascular disease, hypertension, dementia, osteoporosis, asthma, and
  • the disease when it is cancer, it can be leukemia, non-small cell lung cancer, colon cancer, central nervous system cancers, melanoma, kidney cancer, ovarian cancer, renal cancer, prostate cancer or breast cancer.
  • the invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments which are used in the treatment or prevention of the above mentioned diseases.
  • the compounds of the invention may be used in conjunction with procedures involving blood vessels, including vascular surgery, vascular graft and stent patency, organ, tissue and cell implantation and transplantation.
  • the compounds in the invention may also be useful in the treatment of inflammatory diseases, septic shock and the vascular damage associated with infections.
  • the compounds of the invention are useful for the treatment of blood and blood products used in dialysis, blood storage in the fluid phase, especially ex vivo platelet aggregation.
  • the present compounds may also be added to human plasma during the analysis of blood chemistry in hospital settings to determine the fibrinolytic capacity thereof.
  • the compounds in the present invention may also be used in combination with prothrombolytic, fibrinolytic and anti-coagulant agents.
  • the compounds of the invention may also be used in conjunction with protease inhibitor-containing highly active antiretroviral therapy (HAART) for the treatment of diseases which originate from fibrinolytic impairment and hypercoagulability of HIV-I infected patients receiving such therapy.
  • HAART highly active antiretroviral therapy
  • a pharmaceutically effective amount of a compound herein refers to an amount of the compound which will inhibit the serine protease inhibitor PAI-I in the mammal in need thereof to a sufficient extent to provide a desirable improvement in the condition in question or provide sufficient inhibition of the serine protease inhibitor PAI-I to prevent, inhibit or limit the onset of the physiological basis for the malady or condition in question.
  • Compounds of the present invention may be used to treat diseases associated with elevated levels of PAI-I as well as reduced levels of targets of PAI-I.
  • diseases include but are not limited to pulmonary and cardiovascular diseases; cancers, including breast, lung, and ovarian cancers; Alzheimer's disease; and prophylaxis for prevention of the above conditions and others associated with increased PAI-I activity or levels in vivo.
  • Compounds of the invention may be administered to mammalian patients in need of treatment or prophylaxis, in a therapeutically effective amount, consisting of an amount sufficient to provide prophylaxis or treatment of the disease condition in question.
  • Compounds of the invention may be administered alone or in combination with one or more pharmaceutically acceptable carriers, excipients, other medicinally active components, and other pharmaceutically acceptable substances.
  • Compounds of the invention may be administered orally or by injection, either intramuscular or intravenous.
  • Figures 1 through 8 are graphs of PAI-I bound to vitronectin versus concentration in log ⁇ M of compounds according to the invention, as well as control compounds.
  • Figures 9A-9I present dose response curves for anticancer activities of Q012095H.
  • Figures 10A-10I represent dose response curves for anticancer activities of Q011030.
  • Figures 11A-11I represent dose response curves for anticancer activities of Q012098C.
  • the reaction mixture was cooled to r.t. and poured into a cold 5.5 N HCI (500 ml).
  • the product was extracted with diethyl ether (3 x 300 ml), the extract was washed with 5.5 N HCI (2 x 100 ml) and water (3 x 150 ml) and dried over MgSO 4 .
  • Vanillin (30.4 g, 200 mM) was dissolved in ethanol (200 ml). Potassium carbonate (27.2 g, 200 mM) was added and the suspension was stirred at 7O 0 C until it turned to a clear solution. Ethyl ⁇ -bromoisobutyrate (50 g, 250 mM) was added and the mixture was refluxed for 9 hrs. After cooling to r.t. the KBr was filtered off and washed with ethanol. The filtrate was rotavaped down to dryness, diethyl ether (300 ml) was added and the organic layer was washed with NaHCO 3 (5 g) and Na 2 CO 3 (5 g) dissolved in 400 ml of water.
  • the crude product was subjected to chromatographic filtration through silica gel with hexane:ethyl acetate (15% to 35% gradient ethyl acetate) to give pure l,7-bis-[4-(l-ethoxycarbonyl-l- methyl-ethyloxy)-3-methoxyphenyl]-l,6-heptadiene-3,5-dione as a red oil (500 mg, 25%).
  • the assay is based on using a fluorescent substrate (SpectroFluor) to measure residual uPA following inhibition of uPA by PAI-I.
  • PAI-I used in the assay is pre-treated in the presence of increasing concentrations of the lead compounds to screen for any inhibitory effects on PAI-I.
  • Method This assay was performed in 96 well microtiter plates. The concentrations of uPA (8 nM) and PAI-I (6 nM) used in this assay were carefully optimized when using the fluorescent substrate, SpectroFluor. Stock solutions (10 mM) of all lead compounds were prepared fresh in DMSO.
  • the lead compounds do not appear to follow this pharmacological dose-response model with respect to their inhibition of PAI-I, leading to the following two issues: a) it becomes impossible to obtain IC 50 values in the absence of a sigmoidal dose response; b) it is possible that the mechanism by which these compounds interact with PAI-I may not be a typical pharmacological phenomena and/or may involve multiple mechanisms.
  • uPA inhibition serves as a functional index of structural/conform- ational alterations in PAI-I produced by these small molecule inhibitors.
  • Table 1 The data presented in Table 1 provide both the maximum PAI-I inhibition achieved by each compound as well as the concentration of the compound required for the inhibition.
  • This assay was to screen compounds for their inhibitory effects on PAI-I, preventing the interaction of PAI-I with vitronectin. Vitronectin can stabilize PAI-I in active form, enhancing and prolonging its activity.
  • This ELISA assay is based on the interaction of wildtype human PAI-I (aa 110-145) with the N-terminal somatomedin B-like (SMB) domain (aa 1-40) on vitronectin.
  • PAI-I was allowed to bind to vitronectin coated plates.
  • the bound PAI-I was detected with a HRP-conjugated polyclonal goat anti-human PAI-I antibody using a standard ELISA method.
  • PAI-I was pre-incubated with various concentrations of the lead compounds before being allowed to bind to vitronectin.
  • Vitronectin consists of several domains of which the N-terminal amino acids 1-40 portion comprises of a somatomedin B like (SMB) domain which has been proposed to encompass a high-affinity PAI-I binding site. 13 In addition, there are reports regarding additional low-affinity PAI-I binding sites on the C-terminal of vitronectin (aa K348-370). 14 ' 15 It may be reasonably expected that PAI-I binding to these secondary low-affinity sites will not be measured in ELISA method due to extensive washing after the PAI-1/vitronectin incubation.
  • SMB somatomedin B like
  • the mAb was able to significantly block the interaction of the pretreated PAI-I with uPA (functional assay) as well as vitronectin.
  • Table 1 below provides a summary of data obtained in the assays described above.
  • PAI-I Inhibition by Curcuminoid Compounds according to the invention Data from Bioactivity Assays of PAI-I Interaction with u PA, tPA or Vitronectin
  • NCI National Cancer Institute
  • cell suspensions of the human cancer cell lines are diluted according to the particular cell type and their expected target cell density (5000-40,000 cells per well). 100 ⁇ L of the cell suspension is added to each well in a 96-well microtiter plate. Inoculates are allowed a preincubation period of 24h at 37°C for attachment and stabilization. Dilutions of the test compound at twice the intended concentration (in DMSO) are added at time zero (TO) in 100 ⁇ L aliquots to the microtiter plate wells. Usually, the test compounds are evaluated in five dilutions ranging from 10 nM to 100 ⁇ M. Incubations are carried out for 48h in 5% CO 2 and 100% humidity. Cell proliferation is then measured by a protein stain assay using sulforhodamine B. An ELISA plate reader is used to obtain optical densities and the following special concentration parameters are calculated:
  • the GI50 value is a measure of the compound's ability to inhibit growth of cancer cells by 50% as compared to a "control" in the absence of the test compound.
  • the NCI renamed the pharmacokinetic term IC50, the concentration that causes 50% growth inhibition, as the GI50 value since it incorporates a correction for the cell count at time zero when the cells are first added to the microtiter plate wells.
  • the optical density of the test well of cancer cells after a 48 hour period of exposure to the compound is "T", which is a factor in the parameter TGI (total growth inhibition) which measures a compound's cytostatic ability.
  • the LC50 half lethal concentration
  • the control optical density is not factored into the calculation of the LC50.
  • results Compounds according to the invention including Q012095H, Q011030 and Q012098C inhibited growth and proliferation of human primary cell-lines representing various cancers as can be seen in Table 2 below.
  • Dose response curves obtained for Q012095, Q011030 and Q012098C are outlined in Figures 9A-9I, 10A-10I and 11A-11I, respectively.
  • Q012095H had cytotoxic effects on cancer cell-lines representing leukemia, melanoma and cancers of the CNS, colon, kidney, ovary and breast.
  • Other compounds had mainly cytostatic effects with a preferred biological response pattern toward leukemias, melanomas, central nervous system (CNS) and breast cancers.
  • GI50 range for all cell-lines in a disease subpanel is provided.
  • GI50, TGI and LC50 data of the most sensitive cell-line in each disease subpanel is provided.
  • the precise dosage to be employed depends upon several factors including the host, whether in veterinary medicine or human medicine, the nature and severity of the condition being treated, the mode of administration and the particular active substance employed.
  • the compounds may be administered by any conventional route, in particular enterally, preferably orally in the form of tablets or capsules.
  • Administered compounds can be in the free form or pharmaceutically acceptable salt form as appropriate, for use as a pharmaceutical, particularly for use in the prophylactic or curative treatment of atherosclerosis and sequelae (angina pectoris, myocardial infarction, arrhythmias, heart failure, kidney failure, stroke, peripheral arterial occlusion, and related disease states). These measures will slow the rate of progress of the disease state and assist the body in reversing the process direction in a natural manner.
  • atherosclerosis and sequelae angina pectoris, myocardial infarction, arrhythmias, heart failure, kidney failure, stroke, peripheral arterial occlusion, and related disease states.
  • any suitable carrier known to the art can be used to prepare the pharmaceutical compositions.
  • the carrier may be a solid, liquid or mixture of a solid and a liquid.
  • Solid compositions include powders, tablets and capsules.
  • a solid carrier can be one or more substances which may also act as a flavoring agent, lubricant, solubilizer, suspending agent, binder, or tablet disintegrant.
  • the carrier is a finely divided solid, which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, hydroxymethyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like.
  • Encapsulating materials may also be employed with the compounds of this invention, and the term "composition" is intended to include the active ingredient in combination with an encapsulating material as a formulation, with or without other carriers. Cachets may also be used in the delivery of the anti-atherosclerotic medicament of this invention.
  • Sterile liquid compositions include solutions, suspension, emulsions, syrups and elixirs.
  • the compounds of this invention may be dissolved or suspended in the pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both.
  • the liquid carrier is one suitable for parental injection.
  • suitable organic solvents such as propylene glycol or polyethylene glycol.
  • dispersions of the finely divided compounds can be made-up in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, such as arachis oil.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions, can be utilized by intramuscular, intraperitoneal or subcutaneous injection. In many instances a liquid composition form may be used instead of the preferred solid oral method of administration.
  • unit dosage forms of the compounds for standard administration regimes.
  • the composition can be subdivided readily into smaller doses at the physician's direction.
  • unit dosages may be made up in packeted powders, vials or ampoules and preferably in capsule or tablet form.
  • the active compound present in these unit dosage forms of the composition may be present in an amount of from about one gram to about fifteen grams or more, for single or multiple daily administration, according to the particular need of the patient.
  • the daily dose of active compound will vary depending upon the route of administration, the size, age and sex of the patient, the severity of the disease state, and the response to the therapy as traced by blood analysis and the patient's recovery rate.
  • the blood levels of PAI-I and the patient's symptomatic relief analysis may be used to determine whether a larger dose is indicated.
  • the projected daily dose for both human and veterinary use will be from about 25 to about 200 milligrams/kilogram per day, and more usually, from about 50 to 100 milligrams/kilogram per day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des composés pharmaceutiques analogues de la curcumine [bis-l,7-(4-hydroxy-3-méthoxyphényl)-hepta-l,6-diène-3,5-dione] qui agissent en tant qu'inhibiteurs de l'inhibiteur-1 de l'activateur du plasminogène (PAI-1) et peuvent donc être employés dans le traitement prophylactique et thérapeutique de divers états pathologiques liés à la thrombose, incluant la thrombose veineuse profonde, la maladie coronarienne, la fibrose pulmonaire et le syndrome des ovaires polykystiques.
PCT/CA2006/001817 2005-11-07 2006-11-07 Composés curcuminoïdes dans l'inhibition de l'inhibiteur-1 de l'activateur du plasminogène WO2007051314A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73379405P 2005-11-07 2005-11-07
US60/733,794 2005-11-07

Publications (1)

Publication Number Publication Date
WO2007051314A1 true WO2007051314A1 (fr) 2007-05-10

Family

ID=38005402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/001817 WO2007051314A1 (fr) 2005-11-07 2006-11-07 Composés curcuminoïdes dans l'inhibition de l'inhibiteur-1 de l'activateur du plasminogène

Country Status (1)

Country Link
WO (1) WO2007051314A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013010720A (ja) * 2011-06-30 2013-01-17 Uha Mikakuto Co Ltd 新規デヒドロジンゲロン誘導体
US8609717B2 (en) 2010-08-18 2013-12-17 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators
KR101473524B1 (ko) 2012-05-30 2014-12-17 연세대학교 원주산학협력단 당뇨병 합병증 치료용 또는 예방용 의약 조성물
US8962674B2 (en) 2006-11-30 2015-02-24 Tokyo Institute Of Technology Curcumin derivative
US9533976B2 (en) 2013-02-22 2017-01-03 Samumed, Llc γ-diketones as WNT/β-catenin signaling pathway activators
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
US9795550B2 (en) 2014-08-20 2017-10-24 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
JP2018532768A (ja) * 2015-08-26 2018-11-08 ユニベルシタートスクリニカム レーゲンスブルクＵｎｉｖｅｒｓｉｔａｅｔｓｋｌｉｎｉｋｕｍ Ｒｅｇｅｎｓｂｕｒｇ １，７−ジアリール−１，６−ヘプタジエン−３，５−ジオン誘導体、その製造方法および使用方法
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
WO2022232482A1 (fr) * 2021-04-30 2022-11-03 Majeed, Muhammed Compositions pour la gestion du syndrome des ovaires polykystiques
CN116925015A (zh) * 2023-06-16 2023-10-24 黑龙江中医药大学 用于抑制卵巢早衰的活性物质及其制备方法
CN116925015B (zh) * 2023-06-16 2024-06-04 黑龙江中医药大学 用于抑制卵巢早衰的活性物质及其制备方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEVASENA T. ET AL.: "Chemoprevention of Colon Cancer by a Synthetic Curcumin Analog Involves Amelioration of Oxidative Stress", TOXICOLOGY MECHANISMS AND METHODS, vol. 15, 5 September 2005 (2005-09-05), pages 355 - 359, XP008080592 *
KALPANA C. ET AL.: "Inhibition of Nicotine-Induced Toxicity by Curcumin and Curcumin Analog: A Comparative Study", JOURNAL OF MEDICINAL FOOD, vol. 7, no. 4, 2004, pages 467 - 471, XP008080594 *
KAMALAKKANNAN N. ET AL.: "Effect of Curcumin and its Analogue on Lipids in Carbon Tetrachloride-Induced Hepatotoxicity: A Comparative Study", PHARMACEUTICAL BIOLOGY, vol. 43, no. 5, 5 July 2005 (2005-07-05), pages 460 - 466, XP008080593 *
RUKKUMANI R. ET AL.: "Comparative Effects of Curcumin and an Analog of Curcumin on Alcohol and PUFA Induced Oxidative Stress", JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 7, no. 2, 2004, pages 274 - 283, XP003012764 *
SRINIVASAN A. ET AL.: "Protection of Pancreatic beta-Cell by the potential Antioxidant bis-o-Hydroxycinnamoyl Methane, Analogue of Natural Curcuminoid in Experimental Diabetes", JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 6, no. 3, 2003, pages 327 - 333, XP008080628 *
VENKATESWARLU S. ET AL.: "Synthesis and Biological Evaluation of Polyhydroxycurcuminoids", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 13, 2005, pages 6374 - 6380, XP005129311 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962674B2 (en) 2006-11-30 2015-02-24 Tokyo Institute Of Technology Curcumin derivative
US10314832B2 (en) 2010-08-18 2019-06-11 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators
US9884053B2 (en) 2010-08-18 2018-02-06 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators
US8609717B2 (en) 2010-08-18 2013-12-17 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators
US8921413B2 (en) 2010-08-18 2014-12-30 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators
US9303010B2 (en) 2010-08-18 2016-04-05 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators
US9493437B2 (en) 2010-08-18 2016-11-15 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as Wnt/ β-catenin signaling pathway activators
US8629176B1 (en) 2010-08-18 2014-01-14 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators
JP2013010720A (ja) * 2011-06-30 2013-01-17 Uha Mikakuto Co Ltd 新規デヒドロジンゲロン誘導体
KR101473524B1 (ko) 2012-05-30 2014-12-17 연세대학교 원주산학협력단 당뇨병 합병증 치료용 또는 예방용 의약 조성물
US11034682B2 (en) 2013-02-22 2021-06-15 Samumed, Llc Gamma-diketones as wnt/β-catenin signaling pathway activators
US11673885B2 (en) 2013-02-22 2023-06-13 Biosplice Therapeutics, Inc. γ-diketones as Wnt/β-catenin signaling pathway activators
US9533976B2 (en) 2013-02-22 2017-01-03 Samumed, Llc γ-diketones as WNT/β-catenin signaling pathway activators
US10457672B2 (en) 2013-02-22 2019-10-29 Samumed, Llc γ-diketones as Wnt/β-catenin signaling pathway activators
US9951053B2 (en) 2013-02-22 2018-04-24 Samumed, Llc γ-diketones as Wnt/β-catenin signaling pathway activators
US9795550B2 (en) 2014-08-20 2017-10-24 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
US10434052B2 (en) 2014-08-20 2019-10-08 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
US11077046B2 (en) 2014-08-20 2021-08-03 Biosplice Therapeutics, Inc. Gamma-diketones for treatment and prevention of aging skin and wrinkles
US11839679B2 (en) 2014-08-20 2023-12-12 Biosplice Therapeutics, Inc. Gamma-diketones for treatment and prevention of aging skin and wrinkles
JP2018532768A (ja) * 2015-08-26 2018-11-08 ユニベルシタートスクリニカム レーゲンスブルクＵｎｉｖｅｒｓｉｔａｅｔｓｋｌｉｎｉｋｕｍ Ｒｅｇｅｎｓｂｕｒｇ １，７−ジアリール−１，６−ヘプタジエン−３，５−ジオン誘導体、その製造方法および使用方法
US11938233B2 (en) 2015-08-26 2024-03-26 Universitätsklinikum Regensburg 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof
US11191855B2 (en) 2015-08-26 2021-12-07 Universitätsklinikum Regensburg 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof
JP7017208B2 (ja) 2015-08-26 2022-02-08 ユニベルシタートスクリニカム レーゲンスブルク １，７－ジアリール－１，６－ヘプタジエン－３，５－ジオン誘導体、その製造方法および使用方法
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
US11311607B2 (en) 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
WO2022232482A1 (fr) * 2021-04-30 2022-11-03 Majeed, Muhammed Compositions pour la gestion du syndrome des ovaires polykystiques
CN116925015A (zh) * 2023-06-16 2023-10-24 黑龙江中医药大学 用于抑制卵巢早衰的活性物质及其制备方法
CN116925015B (zh) * 2023-06-16 2024-06-04 黑龙江中医药大学 用于抑制卵巢早衰的活性物质及其制备方法

Similar Documents

Publication Publication Date Title
WO2007051314A1 (fr) Composés curcuminoïdes dans l'inhibition de l'inhibiteur-1 de l'activateur du plasminogène
ES2268480T3 (es) Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
JP6059228B2 (ja) ユビキチン特異的プロテアーゼ７の選択的かつ可逆的な阻害剤
US6599925B2 (en) Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
Montanari et al. Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment
US20060178412A1 (en) Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as ibhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2005123089A2 (fr) Composes sulfonamide multicycliques inhibant l'histone desacetylase pour le traitement de maladie
US20030045560A1 (en) 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
Sun et al. Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities
CN102627638A (zh) 噻二唑取代的香豆素衍生物及其作为白三烯生物合成抑制剂的用途
KR100343067B1 (ko) 항종양제 및 항전이제로서 산소-치환된하이드록시쿠마라논 유도체
MXPA06003243A (es) Acidos naftilo benzotiofeno substituidos.
JP2012508194A (ja) アセナフトヘテロ環式化合物、そのシクロデキストリン包接化合物及びシクロデキストリン複合体、並びにそれらがＢＨ３タンパク質類似体、Ｂｃｌ−２ファミリータンパク質の阻害剤の製造における使用
Wang et al. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity
Pati et al. Novel metal chelators thiosemicarbazones with activity at the σ 2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment
Yamaoka et al. Structure–Activity Relationships of New 2-Acylamino-3-thiophenecarboxylic Acid Dimers as Plasminogen Activator Inhibitor-1 Inhibitors
CN109311825B (zh) 2,4,6-三取代均三嗪化合物及其制备方法和应用
Raffa et al. Synthesis, antiproliferative activity and possible mechanism of action of novel 2-acetamidobenzamides bearing the 2-phenoxy functionality
EP1960395A1 (fr) Inhibiteurs de l'inhibiteur 1 d'activateur de plasminogene
JPS64397B2 (fr)
TW200526642A (en) Heterocyclic derivatives
HU197003B (en) Process for producing new isoxazole derivatives and pharmaceuticals comprising same
JPS62174062A (ja) １，５−ベンゾジアゼピン誘導体およびその製造法
KR20240057820A (ko) 신규 피라졸로-옥소티아졸리딘 유도체 및 이를 포함하는 알칼리성 포스파타제 억제제
Hsu et al. 2‐Heteroaryl 2‐Substituted Phenylketone Derivatives and Their Inhibitory Activity on Platelet Aggregation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06804690

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)